Influence of valsartan-eluting stent on neointima formation by Guihua, Li et al.
J Cardiovasc. Dis. Res. Vol 1 / No 1   |  Available Online : www.jcdronline.org  19
Journal of Cardiovascular Disease Research  OPEN ACCESS
ISSN : 0975-3583   © 2010 EManuscript 
Influence of valsartan-eluting stent on neointima formation
Guihua LI MD, *, Lei Wang, MD, Sanqing JIA, MD, Wenlin Ren, MD,*  
Lin ZHAO, MD, Daokuo YAO, MD, Rongjing DING, MD. #
*Cardiovascular center of Chuiyangliu Hospital, Beijing, PRC, 100022 Cardiovascular  
center of Capital University of Medicine Science Affiliated Friendship Hospital, Beijing, 100050,  
China#Department of Cardiology, Cardiovascular Disease Insitution, Peking 
 University People’s Hospital, Beijing 100044, PRC. 
* Correspondence to: Dr. Guihua LI, Cardiovascular center of Chuiyangliu Hospital,  
Beijing, PRC, 100022, E-mail lghua1971@163.com;
Objective :—This study is to explore the effect of valsartan-eluting stents on neointima formation after stenting and to elucidate 
possible mechanisms how locally used valsartan prevents in-stent restenosis (ISR). METHOD: valsartan- and carrier-
eluting stents were manufactured by using multi-layer-coated technology. Bare stents, carrier-eluting stents and valsartan–
eluting stents were implanted into the abdominal aortas of the rabbits respectively. Quantitative angiography (QA) before, 
immediately after and 3 months after stent implantation were compared between the groups of bare (n=8), carrier-eluting 
(n=8) and valsartan-eluting stent (n=10), which allows the comparison of vascular diameters of aortas as well as indices of 
vascular neointimal formation, i.e. luminal area (LA), neointimal area (NIA), inner elastic membrane luminal area (IELA) 
and the maximal inner-membrane thickness (MIT) in 15 rabbits. α-Actin protein expression were detected by Envision 
two-step immunohistochemistry. Mean positive indices (MPI) of the above protein were analyzed semi-quantatively by 
IMS(Information Management System) cell image analysis system. MPI=positive area×OD (optical density). Collagen 
deposition in neointima was observed through MASSON stain among the three groups. 
Result:—the mean aortic diameters were similar in the three groups:bare stents group(n=8), carrier-eluting stents group(n=8) 
and valsartan eluting stents group(n=10) measured by QA at different time. A larger luminal area and a less neointimal 
hyperplasia in valsartan eluting-stents group was found compared with the other two groups. The mean luminal areas 
were 4345548±125822um2; 4302061±167952 um2; 5016269±207934um2 respectively. The mean neointimal areas were 
1119635±163503um2;  1135636±136555um2;  441577±74099um2  and  the  mean  maximal  inner-membrane  thickness 
were 210±30um;192±21um; 116±12um respectively. α-Actin protein expression was significantly lower in neointima of 
valsartan eluting-stents group than the other two groups. Through MASSON stain we found that Collagen was much richer 
in neointima of bare stents group and carrier-eluting stents group than valsartan eluting-stents group.
Conclusion:—Valsartan eluting-stents inhibited neointimal hyperplasia after stenting by decreasing collagen deposition and 
smooth muscle cell proliferation. Therefore it would be potentially effective in preventing in-stent restenosis.
Abbreviations:—Quantitative angiography (QA), luminal area (LA), neointimal area (NIA), inner elastic membrane luminal 
area (IELA), the maximal inner-membrane thickness (MIT), Mean positive indices (MPI), optical density (OD), Drug-
eluting stents (DES), in-stent restenosis(ISR), percutaneous transluminal coronary angioplasty (PTCA), angiotensin α type 
2 receptor (AT2).
Key words: eluting stent, valsartan, restenosis, collagen, AT2 receptor
BACKGROUND
With the extensive use of stents in-stent restenosis is becoming 
a major drawback. A series of intravascular studies confirm 
that  elastic  recoil  and  negative  remodeling  which  caused 
restenosis  after  PTCA  mainly  is  counteracted  by  stents,  so 
in-stent  restenosis  is  mainly  caused  by  intimal  hyperplasia. 
Recently,  impressive  results  have  emerged  in  the  field  of 
ISR  prevention.  Drug-eluting  stents  (DES)  coated  with  the 
strong  antiproliferative  agents  rapamycin  or  paclitaxel  have 
been demonstrated to be potent antirestenotic strategies[1  2]. 
Notwith- standing this tremendous progression in antirestenotic 
therapies, with the use of DES in the “real world,” target vessel 
revascularization  remains  necessary  in  approximately  4%[3]. 
Moreover, some concerns have emerged about the occurrence 
of late thrombosis and hypersensitivity reactions after DES 
implantation[4]  Consequently,  refinement  of  antirestenotic 
therapies  remains  necessary.  Recently,  there  is  an  increasing 
interest in physiological antirestenotic therapies by means of 
restoring the normal biologic function of the vessel wall. A 
lot of fundamental studies have proved that Ang II accelerates 
restenosis  through  acting  with  the  growth  factors.  AT1 
receptor antagonists can reduce restenosis through blocking 
the combination of Ang II and AT1 receptor, reducing the 
concentration of growth factors related with restenosis and 
improving  the  concentration  of  growth  factors  inhibiting Influence of valsartan-eluting stent on neointima formation
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restenosis.  Val-PREST  and  VALVACE  trial  have  confirmed 
that  oral  administration  of  valsartan  reduce  restenosis  rate 
after stenting[8 9] but the mechanism how locally used valsartan 
prevents restenosis remains unclear.
OBJECTIVE
To  explore  the  effect  of  valsartan  eluting  stent  on  intimal 
hyperplasia  after  stenting  and  elucidate  the  possibility  and 
mechanism  of  valsartan  eluting  stent  to  prevent  in-stent 
restenosis.
METHODS
Experimental animals and groups
15  adult  New  Zealand  white  rabbits  (ignorance  of  gender, 
weighting 2.75-3.25kg, provided by Beijing Friendship Hospital 
animal laboratory) were acclimatized to the animal quarters for 
at least one week. They were divided into bare-mental stent, 
carrier-eluting stent and valsartan-eluting stent group according 
to the stent types. There were 5 in each group.
2. Equipment and implantation of stent:
30 316L stainless steel stents with length 10mm and diameter 
3.0mm were chosen, among which 20 stents were manufactured 
into eluted, i.e. 10 valsartan-eluting stents in which Valsartan 
was embedded in base coating in a dosage of hundreds ug/cm2; 
and another 10 carrier-eluting stents, by using the exactly same 
multi-layers coated technique, while 10 were left to be bare 
mental stents. According to the multi-layers coated technique, 
the eluted stents were manufactured with base coating, which 
is  contented  with  organic-inorganic  compound,  and  top 
coating, which is made with high compatible polymer full of 
phospholipid groups. The only difference of the two different 
eluted stents is that Valsartan was embedded in base coating 
during the manufacture in the valsartan-eluting stent, while the 
carrier-eluting stent was not. The animals were anesthetized 
celiacly  with  Ketamine,  the  right  common  femoral  artery 
was  surgically  exposed  and  the  adventitia  circumferentially 
cleared.  A  4-French  arterial  sheath  was  introduced  through 
the incision up to the aorta. Meanwhile, heparin in a dosage 
of 100IU/kg was injected through the sheath. An angioplasty 
balloon (3.0*20mm) with stent was introduced by guiding wire 
(0.014″×190cm) in the superficial femoral artery and advanced 
into the common femoral artery to a standardized location just 
distal to the bifurcation of the renal artery. The balloon was 
inflated to 12–14 atm in 30–60 seconds before it was withdrawn 
and released the stent. The other stent was implanted in the 
same way and the distance between the stents was about 2 
cm.  The  catheter  was  then  removed,  and  the  incision  was 
closed  after  the  implantation.  Regular  injection  of  400000u 
Benzylpenicillin Sodium was administered for 3 days in order 
to prevent infection. All the rabbits were raised for 3 months.
3. Evaluation methods and indices:
Angiographic analysis: Abdominal aorta converse angiography 
was  performed  before,  immediate  after  and  3  months  after 
stents implantation. Diameter, stenosis percent of diameter and 
area of stent section of vessel were analyzed by QA.
Pathological analysis:
Three months later, the rabbits were scarified. The vessels with 
stents were taken out and put into formalin (4%) for fixation, 
then  was  embedded  by  stiff  plastic.  Slices  were  made  by 
polycut slicemachine and were processed with HE, MASSON 
and  picrosirius  staining.  Indices  of  the  vascular  neointimal 
formation, i.e. Inner and external elastic membrane luminal area, 
the maximal intimal thickness, neointimal area and stenosis area 
percent were analyzed by Leica Q550CW image analysis system 
in HE stain. Collagen deposition was analyzed by MASSON 
stain by light microscope. Collagen integral optical density was 
analyzed quantitatively by image analysis system.
Immunohistochemistry:
α-Actin protein expression was detected by Envision two-step 
immunohistochemistry.  Immunohistochemical  staning  was 
performed on formalin-fixed, paraffin embedded sections by 
Envision technique using the kit (Dako Corporation).
Mean  positive  indices(MPI)  analyzed  by  IMS  cell  image 
analysis system was used to evaluateα-Actin semi-quantitatively. 
MPI=positive area×OD (optical density)
RESULTS
1. Stent Implantation
Despite  the  death  of  a  rabbit  during  the  procedure  of 
implantation, we succeeded in implanting 8 bare stens into 4 
rabbits,  10  carrier-eluting  stents  into  5  rabbits(a  rabbit  died 
because of diarrhea later), 10 valsartan-eluting stents into 5 
rabbits.
2. QA analysis
There was no difference between any two of the three groups 
in terms of the mean diameters of the celiac aortic at before, 
immediately  after  or  3  months  after  implantation  by  QA 
comparison. No in-stent restenosis (diameter stenosis >50%) 
was found in any group according to the repeated QCA at 3 
months after implantation(data not shown here).
3. HE Stain Image Analysis of Slices
It was indicated that a significantly larger luminal area (LA) and 
less neointimal hyperplasia was found in valsartan-eluting stent 
group compared with the other two groups. The mean LA of 
bare group, carrier eluting stent group and valsartan-eluting 
stent group were 4345548±125822um2, 4302061±167952 um2 
and 5016269±207934um2 respectively. It was also found that 
the MIT in all three groups were significantly increased at 3 
months  after  implantation.  Furthermore,  MIT  and  NIA  in 
valsartan-eluting group were significantly smaller than those of 
the other two groups with a significantly larger LA as indicated 
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Figure 3 MASSON Stain A: bare-mental stent group; B: carrier-eluting stent group; C: 
valsartan-eluting stent group
Table 1: Results of HE stain
goups ELA(um2) IELA (um2) LA (um2) NIA (um2) MIT(um) PAS(%)
Bare 6406076±177475 5465184±215062 4345548±125822▲ 1119635±163503▲ 240±30▲ 20 ±2.3▲ 
Carrier 6309791±176032 5437697±183248 4302061±167952▲ 1135636±136555▲ 192±21▲ 21±2.3▲
Valsartan 6463743±195148 5457847±162519 5016269±207934 441577±74099 116±12 8±1.5
α-Actin Immunohistochemistry:
α-Actin expressed in intimal and media in both bare-mental stent group and carrier-eluting stent group while it expressed a little fainter in valsartan-eluting stent 
group compared with the other two groups. The mean positive index by image analysis was 463993.2±24298.0 vs 474118.3±15116.3 vs 232219.2±19713.8 in bare-
mental stent group, carrier-eluting stent group and valsartan-eluting stent groups. There was siginificant differences compared valsartan eluting stent group with the 
other two groups (P<0.01) (Figure 2).
4. MASSON Stain Analysis:
A lot of collagen deposition was found in neointima in the 
bare-mental  stent  group  and  carrier-eluting  stent  group  by 
MASSION stain but there was much less collagen found in 
neointima of valsartan-eluting stent group(Figure 3). Integral 
Optical Density of positive target analyzed by collagen image 
analysis system was 2292.5±179.5, 2346.2±119.7, 1320.0±103.8 
respectively in bare mental stent group, EELA:external elastic 
laminal area, IELA: internal elastic laminal area, LA:luminal 
area;NIA  :neointimal  area,  MIT:  maximal  inner-membrane 
thickness,  PAS:percent  of  area  stenosis  compared  with 
valsartan  group  p>0.05;  ▲compared  with  valsartan  group 
p<0.01. carrier-eluting stent group and valsartan-eluting stent 
group. Compared with valsartan-eluting stent group Integral 
Optical Density in bare mental stent and carrier-eluting stent 
were much higher (p<0.01). There was no obvious difference 
between the other two groups.
DISCUSSION
ISR, mainly caused by intimal proliferation [5] almost, is a major 
drawback of percutaneous transluminal coronary angioplasty 
with  stent  placement.  There  are  two  kinds  of  drug-eluting 
stents  widely  used  clinically  to  reduce  restenosis  effectively: 
rapamycin-eluting  stent  and  paclitaxel-eluting  stent  both 
rapamycin and paclitaxel- are strongly anti-proliferative agents, 
they can inhabit SMC proliferation and migration so inhabit 
neointimal  formation  and  reduce  restenosis.  However,  late 
thrombosis,  inflammation,  hypersensitivity  reactions  and 
endothelium healing delay are of major concern. In light of the 
recent interest in more physiological endothelium and arterial 
recovering antirestenotic strategy for the prevention of IRS, 
RAS intervention attracted more research interests. The RAS 
is not the sole factor for restenosis; However, it surely plays 
a part in the pathophysiology, RAS intervention would be an 
attractive way to prevent ISR in a more physiological manner. 
RAS intervention has endothelium-protective properties, even 
in the setting of vascular injury[6 7].
VAL-PREST[8]  and  VALVACE[9]  trials  have  proved  that 
systemically administered AT1 receptor blockade could reduce 
ISR. To study the effect of valsartan eluting-stents on vascular 
neointimal  formation  and  assess  the  feasibility  to  prevent 
restenosis,  we  coated  stents  with  Valsartan  and  carried  out 
animals experiment. The results showed Valsartan eluting-stents 
inhibited neointimal hyperplasia and might play an important 
role in preventing restenosis.
COLLAGEN AND RESTENOSIS
More  recently,  extracellular  matrix  accumulation  has  been 
recognized  as  a  very  important  component  of  in-stent Influence of valsartan-eluting stent on neointima formation
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restenosis  in  the  chronic  phase  after  stent  implantation.  A 
substantial portion of the neointima consists of extracellular 
matrix rather than cells[10]. From 2 to 6 months, stented porcine 
coronary arteries show a reduction in neointimal hyaluronan 
associated  with  reduced  neointimal  type  III  and  increased 
type I collagen[11]. Observations to a more chronic phase of 
neointimal  evolution  have  been  extended  to  more  than  18 
months and found that the neointima in stents in place up to18 
months  remains  hypercellular  (confluent  SMCs)  and  rich  in 
type III collagen, versican, and hyaluronan with relatively little 
type I collagen and decorin. In contrast, stents ≥18 months 
old  demonstrated  weaker  staining  for  versican,  hyaluronan, 
and type III collagen and stronger staining for type I collagen 
and decorin. Neointimal cell density, area occupied by SMCs, 
and in-stent stenosis were smaller in stents≥18 months old 
group compared with stents<18 months old group. These data 
demonstrate that intimal lesions at 18 months after stenting 
resemble wounds that are not fully healed and suggest that 
neointimal retraction occurs subsequently.[12]
RAS and RESTENOSIS
It is known that there are 4 subtype angiotensin II receptors:AT1, 
AT2,  AT3  and  AT4.  RAS  exerts  its  physiological  effects 
through Angiotensin II stimulating angiotensin II receptors, 
especially AT1 and AT2. Activation of the AT1 receptor has 
deleterious effects on the cardiovascular system, namely cell 
migration  and  proliferation,  extracellular  matrix  deposition, 
inflammation, promotion of thrombosis, and production of 
reactive oxygen species. Activation of the AT2 receptor could 
counteract effects of the AT1 receptor Activating. Activation of 
the AT2 receptor is associated with NO production, inhibition 
of proliferation, and induction of apoptosis. Selective AT1 
receptor  blockers  inhibit  stimulation  of  AT1  receptor  by 
Angiotensin ||, the AT2 receptor can still be activated. So 
adverse effects of Angiotensin |, such as cell migration and 
proliferation,  extracellular  matrix  deposition,  inflammation, 
promotion  of  thrombosis,  and  production  of  reactive 
oxygen species, are blocked, and the advantageous effects of 
AT2 activation still remain. AT1 receptor and AT2 receptor 
interacts with each other. Wu et al [13] elucidated the function 
of  the  AT2  receptor  while  AT1  receptor  antagonism  after 
vascular injury. Neointimal formation was attenuated in wild 
mice by AT1 receptor blockade ;this effect was less prominent 
in AT2 knockout mice. Moreover anti-inflammatory effects 
of AT1 receptor blockade were decreased in AT2 knockout 
mice. The conclusion was that stimulation of the AT2 receptor 
during AT1 receptor antagonism is important in the decrease 
of neointimal formation after vascular injury. Furthermore, 
Suzuki et al[14] demonstrated neointimal formation as well as 
DNA synthesis in vascular smooth cells after vascular injury 
was exaggerated in AT2 knockout mice, but they were both 
suppressed in AT1 knockout mice compared with those in 
wild-type mice. In contrast the number of apoptosis cells in 
the injured artery in VSMC was significantly increased in AT1 
knockout mice but decrease in AT2 knockout mice. The result 
suggests AT2 exerts antiproliferative effects and propoptotic 
changes in VSMC by counteracting AT1 in the process of 
neointimal formation after vascular injury. Our study shows 
that  valsartan-eluting  stents,  local  application  of  valsartan, 
could  inhibit  neointimal  formation,  it  may  be  an  attractive 
methods to prevent ISR.
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